Below you'll find a list of all posts from January, 2020
The Chinese pharmaceutical market sees another significant victory in recent weeks as it is announced that China has conditionally approved the first new Alzheimer’s drug to hit the global market in 17 years, and it will be distributed worldwide for long-term testing. The seaweed-derived drug GV-971, more colloquially known as Oligomannate, appears to improve cognition in patients with mild to …
The emergence of a new, potentially dangerous coronavirus in the city of Wuhan in China’s Hubei province has sparked a flurry of articles in the international media and widespread discussion on social media, much of it poorly informed or coloured by politics. With epidemiologists from multiple nations working together to tackle the outbreak, cooperation and the clear exchange of information …
The last decade has seen increasing emphasis worldwide on the importance of well-regulated, real-world data collection and analysis as a follow-up to clinical trials for new medicines and medical devices. China is now taking steps to make regulatory changes of its own in this area. On 7 January 2020, the National Medical Products Association (NMPA) released a paper entitled Guiding …
In January 2017, the US passed new regulations to ensure that all clinical trials would have their results reported within one year of primary completion – with hefty fines of up to US$10,000 a day for those who failed to comply with the new rules. Despite this, a recent study published by The Lancet found that almost six in 10 …
In 2013, Christina Reith, fellow of The Faculty of Pharmaceutical Medicine of the Royal Colleges of Physicians, lead authored a paper that addressed in no uncertain terms what effect red tape was having on clinical trials in Europe. Her conclusions were damning – that for academics engaged in carrying out randomised control trials, the most pressing of issues were those …
